We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Therma Bright Inc | TSXV:THRM | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -20.00% | 0.04 | 0.04 | 0.045 | 0.045 | 0.04 | 0.045 | 2,712,590 | 20:03:03 |
August 28, 2020 -- InvestorsHub NewsWire -- via -- Baystreet.ca - Glenn Wilkins
Making a name for oneself in the very-crowded cannabis industry sometimes involves changing one's look or even one's identity.
No matter what they are called, stocks in the health-care industry (under which cannabis concerns fall) gained 0.8% in the United States, while in Canada, the sector wilted 1%.
Dallas-based Puration, Inc. (OTC: PURA) told investors Thursday it will reveal its new brand name behind its horizontal CBD consumer product expansion into a $500-billion new market opportunity next Tuesday. While it's doing that, PURA will include highlights on its overall expansion plans.
The company's expansion plan is built on a solid base CBD beverage business. The company recently reported $1.6 million in revenue with $471,000 in gross profit primarily from sales of its EVERx CBD Sports Water. Sales YTD grew 48% compared to the same period last year.
PURA shares raced 20.7% by noon EDT Thursday to 1.81 cents, on volume of 21.2 million shares.
On another health front, that of aiming for victories over COVID-19, there's Toronto-based Therma Bright Inc. (TSX-Venture: THRM), which is a progressive medical device technology company. Thursday, the company signed a co-development definitive agreement with Orpheus Medica Inc.
The hookup will allow Therma access to Orpheus' novel biological platform and the joint development of a rapid saliva test for the screening and detection of the virus (SARS-CoV-2) causing COVID-19.
Therma will commit up to $300,000 for Phase 1 (of three) which will focus on the identification of anti-COVID-19 poly-peptides to be utilized in the test prototype development stage. Therma and Orpheus expect Phase 1 to take approximately 45 days to complete. Therma and Orpheus have identified several 3rd party providers to assist with the Phase 1 development path.
THRM shares sprang to life by early afternoon Thursday by 2.35 cents, or 18.8%, to 14.88 cents, on volume of 84,000 shares.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Source: http://www.baystreet.ca/articles/stockstowatch.aspx?id=8627
SOURCE: Baystreet.ca
1 Year Therma Bright Chart |
1 Month Therma Bright Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions